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Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder of unknown etiology, not only
characterized by motor signs but also by non-motor symptoms, including neuropsychi‐
atric and cognitive dysfunction. The results obtained in the last decades show that the
cognitive changes in PD are heterogeneous; impairment in different cognitive domains
such as attention, executive, language, memory, and visuospatial functions can be present
even in the early stages of the disease. Mild cognitive impairment is frequent in non-
demented PD patients and is considered as a risk factor for the development of demen‐
tia. As a response to the heterogeneity of cognitive impairment associated with PD, the
Movement Disorders Society has recently developed formal diagnostic criteria for mild
cognitive impairment and dementia associated with PD. In the present chapter, the authors
have conducted a revision of cognitive impairment in PD, describing the results obtained
in numerous investigations, from the first studies in the1970s to the advances of the last
few years.
Keywords: Parkinson’s disease, review, mild cognitive impairment, dementia, predic‐
tors variables
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder of unknown etiology, characterized
by tremor, rigidity, bradykinesia, and impairment of balance that are usually of an asymmet‐
ric course. The neuropathology of PD affects several structures that are implicated in move‐
ment control. The main neuropathologic feature of PD is the loss of dopaminergic neurons in
the substantia nigra pars compacta, leading to a dysfunction of the frontostriatal system.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Ever since James Parkinson published his best known medical study, entitled “an essay on the
shaking palsy” in 1817, this pathology has awakened scientific interest. Initially, most research
effort focused on the understanding of motor symptoms and the search for effective treat‐
ment options. Levodopa, a precursor of dopamine, was discovered in the 1960s, and years later
would be used as an effective treatment for the motor symptoms of PD. Coinciding with this
historic landmark, a significant increase in interest in the non-motor symptoms associated with
PD began to be observed, with special attention being paid to the cognitive symptoms, because
of their impact on the quality of life of patients.
This chapter focuses on cognitive impairment in PD, from the first studies that paid atten‐
tion to cognitive deficits to the present day concept of dementia associated to PD (PDD). There
is a description of the neuropsychological profile classically associated with PD, going into the
concept of mild cognitive impairment in PD (PD-MCI) in greater depth, which has given rise
to numerous investigations in recent years. There is also a summary of the most relevant
clinical and demographic variables associated with cognitive impairment in PD.
2. Cognitive impairment in PD: a historical review
2.1. First studies
PD is a neurodegenerative disorder described for the first time in 1817 by James Parkinson [1].
In the monographic entitled “an essay on the shaking palsy,” the author described the clinical
characteristics of a limited series of PD patients (Paralysis agitans). He defined the patholo‐
gy as “Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
when supported; with a propensity to bend the trunk forwards, and to pass from a walking to a running
pace” and affirmed that “the senses and intellects being uninjured”. However, subsequent studies
showed that the last statement is not correct.
Charcot [2], is among the first authors to describe changes in mental functioning in PD. The
author stated that in PD patients “…the mind becomes clouded and the memory is lost”. Howev‐
er, it was not until the 1960s and 1970s, coinciding with the first levodopa treatments, that
scientific interest of the cognitive disorders associated with this pathology increased signifi‐
cantly. Over the following years, and even during 1980s, investigations were carried out
without excessive control over the clinical variables (cause of Parkinsonism, stage of disease,
duration of illness, etc.). An example is the study of Reitan and Boll [3]. These authors selected
a group of 25 PD patients and twenty five controls matched on sex, age, and education, which
were evaluated with a battery of psychological tests. The results showed that PD patients
suffered deterioration in general cognition, memory, problem-solving, abstract reasoning, and
organizing abilities. This was a pioneer study in the use of a wide assessment of cognitive
functions. However, information about the clinical features of the patients was not provided
(disease stage, duration, motor symptoms, etc.).
The study of cognitive deficits associated with PD and other neurological diseases character‐
ized by basal ganglia pathology, such as Huntington’s disease and progressive supranuclear
palsy, gave rise to the concept of subcortical dementia, as opposed to predominantly cortical
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dementia characteristic of Alzheimer’s disease [4, 5]. In this period, the concept of subcorti‐
cal dementia is frequently associated in the literature with descriptions of cognitive impair‐
ment in PD. However, different authors consider that this label is often inaccurate and
misleading because its application is not always suitable when referring to the cognitive
impairment in PD; patients with PD may have cognitive deficits, without significantly affecting
their daily lives [6, 7].
The discussions generated by the association between PD and the concept of subcortical
dementia led to the development of numerous investigations with an increase in the interest
in the control of clinical variables (disease stage, duration, motor symptoms, depression, etc.)
and with more exhaustive neuropsychological evaluations [8–11]. The investigation conduct‐
ed by Lees and Smith [12] is among the first studies to consider these characteristics. The
authors conducted a careful sample selection according to the different variables related to the
disease; they selected a sample of PD patients, in early-mid-stage of the disease (Hoehn and
Yahr stage I–II), under 65 years of old, without depression and without antiparkinsonian
drugs. The instruments administered included measures of general intelligence, executive
functions, and memory. The PD patients only showed deficits in executive functions. Various
investigations, such as the study of Lees and Smith [12], were performed in the 1980s and
1990s, and they led to the establishment of the neuropsychological profile classically associ‐
ated with PD.
2.2. Neuropsychological profile of PD
Cognitive deficits in PD have traditionally been seen as an executive dysfunction secondary
to frontostriatal system impairment. In this schema, this executive dysfunction is responsi‐
ble for other cognitive disturbances that can appear in this pathology. However, the recently
obtained results, in the last few decades, show that the cognitive changes in PD are more
heterogeneous than initially thought. PD patients can have deficits in multiple cognitive
domains including the executive functions but also in processing speed, attention, visuospa‐
tial functions, memory, and language. As will be seen below, the heterogeneity of cognitive
impairment associated with PD cannot be explained exclusively as a consequence of dysex‐
ecutive syndrome.
PD is associated with cognitive slowing (bradyphrenia). Numerous studies have used reaction
time tasks to evaluate processing speed and found that PD patients have deficits in simple and
choice reaction time tests [13–18]. However, other investigations show that PD patients only
present an altered execution in the choice reaction time task [19, 20]. The results of a meta-
analysis conducted by Gauntlett-Gilbert and Brown [21] showed that patients exhibit an
altered performance in simple and choice reaction time tasks, but the magnitude of the deficits
was associated with the test complexity. This result has been explained in terms of a limita‐
tion of resources in tasks with more cognitive demands. Processing speed was also meas‐
ured by Symbol Digit test and similar instruments; PD patients showed an altered execution
with this type of test [22].
As regards attention and working memory, PD patients tend to perform normally in verbal
tasks, such as digit span [22, 23], while their execution in visuospatial tasks is altered (visual
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span) [23, 24]. Siegert et al. [25] conducted a meta-analysis including 56 studies. They differ‐
entiated the working memory tests according to the stimuli characteristic (verbal, visual) and
difficulty level (direct, inverse). The results showed that PD patients performed poorly in all
the working memory tasks. However, in the verbal tests, the difficulty was more significant
in the more complex tasks (inverse), while patients showed significant difference in simple
and complex tasks in visual tests. Other authors studied working memory based on the n-back
paradigm and found that patients had deficits, compared to controls, unrelated to the level of
demand or the nature of the stimuli [26].
Visuospatial functions tend to be altered in PD, even in the early stage of the disease. Different
authors reported an altered performance in judgment of line orientation [23, 27], facial
recognition test [28, 29], and visuospatial reasoning such as Raven’s test [8, 10]. Block design
[27–30] and the copy of Rey Complex figure test [27, 29] were other instruments in which PD
patients showed poor execution. It should be noted that the motor component involving this
type of tasks was not controlled in most of these investigations.
Executive functions include a complex set of processes that has been defined as wide and
diverse. Lezak [31] define the executive functions as those skills to respond adaptively to novel
situations: “The executive functions can be conceptualized as having four components: (1) volition; (2)
planning; (3) purposive action; and (4) effective performance. Each involves a distinctive set of activity-
related behaviors. All are necessary for appropriate, socially responsible, and effectively self-serving adult
conduct” (page 650).
The Wisconsin Cart Shorting Test (WCST) is one of the most widely used instruments for the
assessment of executive functions; it measures the ability to form abstract concepts, develop
strategies and use feedback to maintain or change the mental set on the objective. Numerous
authors found that PD patients show an altered performance in this test, including less
categories and a greater number of errors (e.g., see [32, 33]). Verbal fluency (VF) tests were also
used to evaluate executive functions, as they are considered measures of cognitive flexibility
and search strategy. Henry and Crawford [34] propose that phonetic fluency has more validity
and specificity as a frontal impairment measure, compared with the WCST. The results
obtained in PD with measures of VF are highly heterogeneous, both with phonetic and
semantic fluency tests; different studies found an altered execution in PD patients [35–37],
whereas other authors do not report the same results [38–40]. Henry and Crawford [41] studied
the VF in PD by a meta-analysis that included 68 investigations and a total of 4644 partici‐
pants. They found that PD is associated with a deficit in VF, with a greater involvement of
semantic fluency in comparison with the phonetic fluency test. The difficulties are greater
when versions of these tasks in which alternate consigns are used. According to the authors,
the performance in VF in PD patients is not exclusively attributable to a deficit of executive
functions (according to scores on the WCST); the relationship between the deficit of denomi‐
nation task and VF performance suggests that PD is associated with a deficit in the recovery
of information from semantic memory. Furthermore, the action fluency test has been consid‐
ered an alternative VF measure of executive functions, since verb generation is strongly
associated with the prefrontal cortex. PD patients show a poor performance with this task
compared to controls [42].
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Other instruments used to evaluate the executive functions in PD are the Trail Making Test
(part B) and the Stroop test. As for the Trail Making Test, PD patients often have an altered
performance [13, 19, 27]. However, with respect to the Stroop test, the results are heterogene‐
ous: some authors report an altered performance in PD patients [15, 37, 43], whereas other
research studies do not describe the same results [20, 22].
Regarding memory deficits in PD, classical descriptions consider that the alterations are
confined to new information acquisition and spontaneous retrieval; the patients would show
a normal performance in cued recall and recognition tasks. However, the results obtained in
different investigations confirm that the affectation of memory functions in PD is more
complex. PD patients often show an altered performance in different memory tests (Verbal
Paired Associates, Logical Memory) [6, 44, 45], with a normal execution in recognition [44].
However, patients can perform poorly, compared to controls, even in recognition memory
tasks [6]. Using tasks that allowed a more precise examination of different memory compo‐
nents (e.g., the Auditory Verbal Learning Test and the California Verbal Learning Test), some
authors reported deficits in learning and spontaneous recall, without alteration in recogni‐
tion [27, 37, 46]. However, this impairment pattern was not confirmed by other authors who
found alterations in cued recall and recognition [47–50]. Whittington et al. [51] conducted a
meta-analysis and concluded that PD patients have recognition deficits. Therefore, alteration
of the verbal memory in PD is not exclusively limited to a deficit of information retrieval.
In regard to visual memory, there are fewer studies than those which are focused on verbal
memory. The results obtained are diverse, probably as a consequence of the wide range of
instruments used (Visual Retention Test, Visual Paired Associates, Face Memory Test,
Complex Figure Test, etc.) [27, 45, 46, 52]. Visuospatial learning has been evaluated by Pillon
et al. [53, 54] who found that PD patients present an altered execution. This result was
confirmed in a more recent research study [23].
The first research studies into language functions in PD considered that the linguistic deficits
observed in patients were a consequence of motor symptoms. Speech disorders were associ‐
ated to alterations of phonation, facial musculature, reflections, articulation, and prosody [55–
57]. However, in addition to the deficits described above, other alterations related to lan‐
guage production and comprehension are common in PD patients. The results of different
studies show alterations in speech related to a lower proportion of sentences which are
grammatically less complex [58–60]. On the other hand, the results obtained with the Boston
naming test are not conclusive: some authors show an altered execution [8, 61], whereas other
studies do not observe the same results [6, 44, 62]. Other investigations have been focused on
the differentiation between the naming of actions and objects, based on the association of action
generation with the frontal cortex. PD patients showed an altered performance in both naming
tasks (naming and action), but the execution in the action naming was poorer than the naming
of objects [63–65].
As for language comprehension in PD, it is worth mentioning the research line developed by
the Grossman group. They reported the following results in a series of publications: patients
had a normal performance in simple sentences and a deficient execution in complex senten‐
ces, with greater difficulty in those with subordinate clauses; patients show more difficulty
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when analyzing sentences with subordinate clauses, when the semantic information does not
allow their understanding; patients make more mistakes in tasks requiring the matching of a
sentence with a picture and patients show deficits when identifying phonetic errors in
grammatical morphemes, such as pronouns. Taking all the results together, the authors
concluded that PD patients show deficit in language comprehension, related to the limita‐
tion of cognitive resources including, attention, cognitive slowing and working memory [66–
70]. However, other results do not confirm the conclusions of Grossman [66]. Skeel et al. [62]
showed that the alterations of comprehension can be present even in simple sentences and that
this deficit was not associated with the status of working memory. Other authors have recently
described similar results to Skeel et al. [62]; Galtier et al. [47] reported deficits in language
comprehension that cannot be exclusively explained by a limitation of cognitive resources.
In summary, the results obtained in a large number of research studies over the last 40 years
confirm that the cognitive deficits associated with PD are heterogeneous, including altera‐
tions in different cognitive domains such as attention, memory, executive functions, lan‐
guage, and visuospatial functioning. In addition, these data also confirm that the cognitive
alterations in PD patients cannot be exclusively reduced to an executive dysfunction, as has
traditionally been thought.
3. Mild cognitive impairment in PD
3.1. Concept of PD-MCI
Reisberg et al. [71] published the Global Deterioration Scale (GDS) in 1982 describing seven
stages from normal to severe dementia associated with Alzheimer’s disease. The GDS
differentiates between stage 2 in which persons complain of memory deficits (without objective
evidence in clinical interview, in employment or social situations) and stage 3 which was
initially termed “mild cognitive decline”. Clinical deficits appear in stage 3 although the
objective evidence of memory deficit is only obtained by means of an intensive interview
conducted by a clinician. In addition, decreased performance becomes manifest in demand‐
ing employment and social situations. Stage 3 is different to a GDS 4 stage which is consid‐
ered as the earliest stage of dementia. Deficits are manifest in many areas in stage 4 and patients
can no longer perform complex tasks accurately and efficiently. A cross-sectional study in 1988
used the terminology “mild cognitive impairment” (MCI) for the first time to refer the GDS
stage 3 [72]. The results showed that MCI patients performed poorly in different cognitive
measures, compared to GDS stage 2 subjects group (subjective deficits only). In addition, the
group with mild dementia (GDS stage 4) performed significantly more poorly than the MCI
group in the Mini-Mental State Examination and other cognitive measurements.
The concept of MCI was developed and popularized years later by Petersen et al. [73] who
proposed the following diagnostic criteria: (1) memory complaint, preferably corroborated by
an informant; (2) objective memory impairment; (3) normal general cognitive function; (4)
intact activities of daily living; (5) not demented. The International Working group on Mild
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Cognitive Impairment statement in 2004 recommended the criteria which are currently
accepted [74] (Table 1).
Inclusion criteria
• Not normal, not demented [does not meet criteria (DSM IV, ICD 10) for a dementia syndrome]
• Cognitive decline:
-Self and/or informant report and impairment on objective cognitive tasks
And/or
-Evidence of decline over time on objective cognitive tasks
• Preserved basic activities of daily living and minimal impairment in complex instrumental functions
Adapted with permission from Winblad et al. [74]. © 2004 Blackwell Publishing Ltd.
Table 1. General criteria for MCI.
The construct of MCI in PD (PD-MCI) is a more recent concept, as a result of the gradual
increase of interest in non-motor symptoms, the heterogeneity of cognitive deficits, and their
impact on the quality of life of PD patients. The investigation of Janvin et al. [75] was the first
study that focused on PD-MCI; it included 76 PD patients who were evaluated with a limited
selection of neuropsychological tests (Benton Visual Retention Test, Judgment of Line
Orientation test, Stroop Word Test). Forty-two patients had PD-MCI (55%), defined as scoring
−2 standard deviations below the mean of the control group in at least one of the tests. In the
PD-MCI group, 57% of the patients had an altered performance in one neuropsychological
test, 33% in two tests while the remaining 10% had an altered execution in all the three tests.
In a recent review conducted by Litvan et al. [76], the authors reported that between 18.9%
and 38.2% of PD patients met MCI criteria. However, the study of Janvin et al. [75], descri‐
bed above, and other investigations have reported results with higher percentages (51–55%)
[77, 78]. These discrepancies can be explained by differences in the PD-MCI diagnostic criteria,
number of cognitive domains explored or selection and number of neuropsychological tests
used. Several studies used a less restrictive level (−1 standard deviation) to determine cognitive
impairment, while other authors opted for a −1.5 standard deviation or −2 standard devia‐
tion cut-off. For example, Foltynie et al. [79] evaluated a group of 159 PD patients with different
cognitive tests, including a pattern recognition memory, spatial recognition memory and the
Tower of London task from the CANTAB battery. The results showed that 36% of PD patients
were considered cognitively impaired, defined as scoring ≥1 standard deviation below the
normative mean of at least one of the tests. Janvin et al. [80] conducted a study of cognitive
function in a sample of 145 PD patients. Subjects with Mini-Mental State Examination score
<25 were considered demented and excluded. Of the total sample, 72 PD patients without
dementia were studied and compared to 38 normal controls. Of the nondemented PD
patients, 52.8% were diagnosed with MCI, defined as impaired performance [−1.5 standard
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deviation or more below the mean of the control group) in one, two, or all three of the given
neuropsychological tests (Benton Visual Retention Test, Judgment of Line Orientation test,
Stroop Word Test). In the study of Muslimovic et al. [81], the authors opted for a −2 stand‐
ard deviation cut-off. They assessed a sample of 115 nondemented newly diagnosed PD
patients with neuropsychological tests which examined the following six cognitive domains:
psychomotor speed, attention, language, memory, executive functions, and visuospatial.
Cognitive dysfunction was considered to be present whether performance in three or more
neuropsychological tests was impaired. The results showed that 27 PD patients (23.5%) had
cognitive dysfunction.
As one can see, there has been no consensus on the number of tests that need to be consid‐
ered as altered to establish a diagnosis of MCI; alteration in one or more tests was taken as a
criterion for the diagnosis of MCI [80], while other authors consider that impairment should
be present in at least three tests (either within a single cognitive domain or across different
cognitive domains) [81]. Moreover, most of the studies used brief batteries or a set of neuro‐
psychological tests that do not allow the evaluation of all cognitive domains with a sufficient
level of accuracy. Some authors described cognitive impairment as defined by poor perform‐
ance in a selection of tests from the CANTAB battery (pattern recognition memory, spatial
recognition memory and the Tower of London task) [82]. Other research only evaluated four
cognitive domains, including memory, executive, attention, and visuospatial. Only one test
was used for the case of memory and attention. Moreover, visuospatial function was exam‐
ined by one item of the Montreal Cognitive Assessment test, which is a screening instrument
[83]. Muslimovic et al. [81] selected a wide range of neuropsychological tests to examine
cognitive functions in the following six domains: psychomotor speed, attention, language,
memory, executive functions, and visuospatial/constructive skills. However, not all the
domains were studied in the same degree of detail; although the memory and executive
domains were investigated in depth by up to six tests, only the Boston Naming Test was used
for the language examination.
3.2. Diagnostic criteria for PD-MCI
As a response to the heterogeneity mentioned above, the Movement Disorder Society (MDS)
commissioned a task force to develop formal diagnostic criteria for PD-MCI which were
published in 2012 [84]. The criteria proposed by the MDS are intended to overcome most of
the previously described limitations. The MDS task force proposes a uniform method to
characterize and diagnose PD-MCI, providing a framework to advance the understanding of
this pathology. The proposal of the task force sets out new objectives for the following years
(Table 2).
I. Inclusion criteria
• Diagnosis of Parkinson’s disease as based on the UK PD Brain Bank Criteria [124]
• Gradual decline, in the context of established PD, in cognitive ability reported by either the patient or informant, or
observed by the clinician
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• Cognitive deficits on either formal neuropsychological testing or a scale of global cognitive abilities
• Cognitive deficits are not sufficient to interfere significantly with functional independence, although subtle difficulties
on complex functional tasks
II. Exclusion criteria
• Diagnosis of PD dementia based on MDS Task Force proposed criteria [123]
• Other primary explanations for cognitive impairment (e.g., delirium, stroke, major depression, metabolic
abnormalities, adverse effects of medication, or head trauma)
• Other PD associated comorbid conditions (e.g., motor impairment or severe anxiety, depression, excessive daytime
sleepiness, or psychosis) that, in the opinion of the clinician, significantly influence cognitive testing
Adapted with permission from Litvan et al. [84]. © 2012 Movement Disorder Society.
Table 2. MDS Criteria for the Diagnosis of PD-MCI.
The MDS criteria included a two-level operational schema that differs in the comprehensive‐
ness of the neuropsychological testing. Level 1 criteria provide less diagnostic certainty than
level 2: (A) Impairment on a scale of global cognitive abilities or impairment on a limited
battery of neuropsychological tests. When a limited battery of tests is performed, impair‐
ment must be present in at least two tests for a diagnosis of PD-MCI (level 1); (B) Compre‐
hensive neuropsychological testing that includes two tests in each of the five cognitive
domains (attention and working memory, executive, language, memory, and visuospatial).
Impairment should be present in at least two tests, either within a single cognitive domain or
across different cognitive domains (level 2). In addition, impairment in neuropsychological
tests may be demonstrated by performance approximately 1–2 standard deviations below age,
education, gender, and culturally appropriate norms; or a significant decline demonstrated in
serial cognitive testing; or a significant decline from estimated premorbid levels.
As proposed by the MDS task force, classification of PD-MCI subtypes is important for research
purposes and for exploring whether impairments in different cognitive domains have a
different neurobiological substrate and course. Comprehensive neuropsychological testing is
required (level 2) for the PD-MCI sub-types classification. The use of two tests in each cognitive
domain for the level 2 category examines all cognitive domains equally, can increase sensitiv‐
ity and allow full subtyping of PD-MCI. The presence of two altered tests within a single
cognitive domain, with the other domains unimpaired, represents a single domain subtype.
Whether at least one test in two or more cognitive domains is impaired, then PD-MCI should
be subtyped as multiple domain. The proposed MDS criteria recommend not using amnestic
or nonamnestic terminology. Instead, specification of the affected domains is preferable so that
potential differences among subtypes may be better analyzed in futures studies.
Up to now, only a few studies have provided data with the MDS PD-MCI criteria. Broeders et
al. [85] examined a group of 123 newly diagnosed PD patients and found that PD-MCI was
present in 35% of cases, when level 2 was applied (comprehensive assessment). In a more recent
investigation, Stefanova et al. [86], applying level 2 of the MDS criteria, examined 111 early
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PD patients and 105 healthy matched control subjects; PD-MCI was present in 24% of the
patients. The differences in percentages compared to the study of Broeders et al. [85] can be
explained by the clinical characteristics of PD patients; Stefanova et al. [86] included patients
in stage 1 (Hoehn and Yahr] while the patient sample of the Broeders et al. [85] study were in
stages 1 and 2. Pedersen et al. [87] examined a sample of 182 PD patients (Hoehn and Yahr
stage 1–2), applying level 1 (brief assessment) of the MDS criteria and found that 20.3% of
patients met MCI criteria. Other authors evaluated patients who had a mean PD duration of
5.2 and 14.1 years and found that PD-MCI was present in 33–42.6% of the patients respective‐
ly, when level 2 was used [88, 89]. Recently, Galtier et al. [90] showed that 60.5% of the patients
were diagnosed with PD-MCI according to level 2 MDS criteria. The percentage of PD-MCI in
this study was slightly higher than that obtained in previous studies. These differences could
be explained by the tests used to assess the linguistic domain. The authors included an
assessment of language comprehension, unlike the methodology used in previous investiga‐
tions. Most of the studies that applied the MDS task force criteria used −1.5 SD cut-off [85, 87,
89, 90]. Goldman et al. [91], using a cut-off of 2 SD below norms, reported that 61.8% of
patients (mean PD duration of 9.3 years) were classified as PD-MCI with level 2 of the MDS
criteria. The subtype categorization showed the high predominance of the multiple-domain
PD-MCI with percentages of between 84 and 96% [90, 92, 93].
4. Relationship between cognitive impairment in PD and clinical
variables
There are many research studies which have studied the relationship between cognitive
impairment and potential predictor variables. Cognitive performance has been related to the
neurological impairment, duration of illness, age at onset of PD, depressive symptoms and
educational level, among others. As we shall see, the results are diverse which could once again
be interpreted as a reflection of the heterogeneity of cognitive impairment in PD.
Regarding neurological impairment, different investigations have opted for correlation
analysis and found that the degree of neurological impairment was associated with poor
performance in visuospatial functions [28, 94], processing speed [95], working memory [24],
procedural learning [37] and executive functions [96, 97]. However, other authors have not
confirmed these results finding no relationship between the neurological impairment and
different cognitive functions, such as processing speed [98], visuospatial functions [99], or
procedural learning [100, 101]. Neither has an association with declarative memory [53, 100,
102] or linguistic functions (comprehension sentences, verbs generation) [67, 103–105] been
found.
Other investigations compared PD patients with different levels of neurological impairment
according to the Hoehn and Yahr scale. Although these studies are less frequent, patients with
mid-late PD (according to Hoehn and Yahr stage) often present more affectation in different
cognitive domains. The investigation conducted by Huber et al. [8] was one of the first studies
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that examined cognitive performance by comparing patients with different stages of PD.
Moderate-to-late stage patients performed poorly in visuospatial functions, memory, execu‐
tive functions, and naming. The results of Huber et al. [8] are clear evidence that the deterio‐
ration in the PD is not homogeneous, but that it is linked to the severity of the disease. Other
authors also found differences in cognitive functions related to neurological impairment. For
example, late disease stage patients showed poor performance in immediate memory
(verbal and visual) [106], and executive functions (alternating series) [20].
Quite a few investigations pay attention to the relationship between illness duration and
cognitive impairment. Research studies using correlation analysis showed that disease
duration was not associated to processing speed [95, 98], working memory [10, 102], proce‐
dural learning [37], visuospatial functions [107], executive functions [10, 96], or sentence
comprehension [67, 108, 109]. The results are more heterogeneous for other cognitive func‐
tions such as memory; some authors showed that disease duration was related to poor
performance in diverse memory tests [10], while others did not find similar results [53, 110].
Other authors have demonstrated that cognitive dysfunction occurs even at the time of PD
diagnosis. Foltynie et al. [79] showed that 36% of newly diagnosed PD patients had signs of
cognitive impairment based on their performance in a pattern recognition memory task and
in the Tower of London task. Similarly, Muslimovic et al. [81] examined a sample of newly
diagnosed PD patients and found poor performance in different cognitive tasks; the differen‐
ces when compared to normative data could mainly be explained by measures of immediate
memory and executive function.
The age at onset of the disease has been associated with an increased risk of cognitive
impairment, in other words the older the age at onset, the greater risk of cognitive decline, as
measured with the Mini-Mental State Examination [111]. The study of relationship between
age at onset of the disease and different cognitive functions revealed that the older the patient
was at onset, the more likely the patient was to perform poorly in declarative memory
(verbal and visual), executive, visuospatial and language functions (naming) [10, 15, 112, 113].
Depression is among the most common neuropsychiatric disturbances in PD. Different studies
have concluded that between 36 and 60% of patients show depressive symptoms [114–116].
Numerous investigations have focused on the association between cognitive impairment and
depression in PD. Depression has been associated with poor performance in global cogni‐
tion, as measured by instruments such as the Mini-Mental State Examination or the Demen‐
tia Rating Scale [116–118]. Some authors who have studied the relationship between depressive
symptoms and specific cognitive functions showed that depression was related to poor
performance in different measures of executive functions [11] and in the comprehension of
complex sentences [62]. However, other authors did not find any connection between
depression and different cognitive functions, including processing speed [95], visuospatial
functions [99], declarative memory [48], procedural learning [101], or sentence comprehen‐
sion [67].
Certain authors have compared PD patients with and without depression by means of a
comprehensive neuropsychological assessment. The results showed that patients with
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depressive symptoms presented an altered performance in declarative memory and seman‐
tic fluency, without showing differences in verbal span, phonetic fluency, concept formation,
or naming. However, when both groups of patients (with and without depression) were
equated according to the Dementia Rating Scale no differences were found between the
groups [119]. Ng et al. [120] recently looked into the influence of depression in cognitive
functions using a longitudinal study. They examined eighty one PD patients who were
classified into two groups; with and without depression, according to the score in the Geriatric
Depression Scale (score ≥5 was required for depression diagnosis). The results showed that
PD patients with depression had a slightly lower performance in global cognition, as meas‐
ured by the Mini-Mental State Examination and the Montreal Cognitive Assessment test,
although these differences did not reach statistical significance. On the other hand, no
differences were found between patients with and without depression in a set of neuropsy‐
chological tests that included measures of attention, memory, executive, visuospatial, and
language functions. An 18 month longitudinal study was conducted, and similar results to the
baseline were found; both groups of patients did not differ in global cognition and cognitive
measures. Therefore, although the depression in PD appears to have some effect on global
cognition and some specific cognitive functions, the available results suggest that both
depression and cognitive impairment evolve independently in this pathology.
As regards the study of clinical variables associated with PD-MCI, according to the new MDS
task force criteria, the available data are still limited. The study of Pedersen et al. [87] found
that patients with PD-MCI were older, had less education, longer disease duration and higher
Hoehn and Yahr stage than patients without PD-MCI. Hobson and Meara [93] showed that
PD-MCI was associated to increasing age and worsening motor function. Galtier et al. [90]
reported that PD-MCI was associated with lower education and higher neurological impair‐
ment, as measured by the Hoehn and Yahr scale, although they did not find age of onset or
duration to be important factors.
5. Dementia in PD
As we have seen in first section of the present chapter, the interest in dementia associated to
PD patients dates back to the 1960s and over the last 30 years there have a large number of
studies into the epidemiology of PDD. Aarsland et al. [121] conducted a review of 4336 patients
in 27 studies and showed that the mean prevalence of PDD was 40%. The prevalence of
dementia increased from 28% after 5 years of follow-up, to 48% at 15 years, and up to 83%
after 20 years. Moreover, PDD has been associated with increased mortality; after 20 years of
follow-up of newly diagnosed PD patients 100 of 136 (74%) have died [122].
The Movement Disorder Society (MDS) recruited a Task Force to define the clinical diagnos‐
tic criteria for PDD which were published in 2007 [123]. The defining feature of PDD is that
dementia develops in the context of established PD. Hence, diagnosis of idiopathic PD
(based on the UK PD Brain Bank Criteria) [124] before the development of dementia symp‐
toms is the essential first step in the diagnosis. Diagnosis of dementia must be based on the
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presence of deficits in at least two of the four core cognitive domains (attention, memory,
executive, and visuospatial functions) as shown in clinical and cognitive examination, and be
severe enough to affect normal functioning. Neuropsychiatric and behavioral symptoms are
frequent, but are not invariable (Table 3). Clinical diagnostic criteria for probable and possible
PDD are proposed by the MDS (Table 4).
I. Core features
1. Diagnosis of Parkinson’s disease according to Queen Square Brain Bank criteria
2. A dementia syndrome with insidious onset and slow progression, developing within the context of established
Parkinson’s disease and diagnosed by history, clinical, and mental examination, defined as:
• Impairment in more than one cognitive domain
• Representing a decline from premorbid level
• Deficits severe enough to impair daily life (social, occupational, or personal care), independent of the impairment
ascribable to motor or autonomic symptoms
II. Associated clinical features
1. Cognitive features:
• Attention: Impaired. Impairment in spontaneous and focused attention, poor performance in attentional tasks;
performance may fluctuate during the day and from day to day
• Executive functions: Impaired. Impairment in tasks requiring initiation, planning, concept formation, rule
finding, set shifting or set maintenance; impaired mental speed (bradyphrenia).
• Visuospatial functions: Impaired. Impairment in tasks requiring visual-spatial orientation, perception, or
construction
• Memory: Impaired. Impairment in free recall of recent events or in tasks requiring learning new material,
memory usually improves with cueing, recognition is usually better than free recall
• Language: Core functions largely preserved. Word finding difficulties and impaired comprehension of complex
sentences may be present
2. Behavioral features:
• Apathy: decreased spontaneity; loss of motivation, interest, and effortful behavior
• Changes in personality and mood including depressive features and anxiety
• Hallucinations: mostly visual, usually complex, formed visions of people, animals or objects
• Delusions: usually paranoid, such as infidelity, or phantom boarder (unwelcome guests living in the home)
delusions
• Excessive daytime sleepiness
III. Features which do not exclude PD-D, but make the diagnosis uncertain
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• Co-existence of any other abnormality which may by itself cause cognitive impairment, but judged not to be the cause
of dementia, e.g. presence of relevant vascular disease in imaging
• Time interval between the development of motor and cognitive symptoms not known
IV. Features suggesting other conditions or diseases as cause of mental impairment, which, when present make it
impossible to reliably diagnose PDD
• The cognitive and behavioral symptoms appearing solely in the context of other conditions such as:
Acute confusion due to
a. Systemic diseases or abnormalities
b. Drug intoxication
Major Depression according to DSM IV
• Features compatible with “Probable Vascular dementia” criteria according to NINDS-AIREN
Adapted with permission from Emre et al. [123]. © 2007 Movement Disorder Society.
Table 3. Features of PDD.
Probable PDD
1. Core features: Both must be present
2. Associated clinical features:
• Typical profile of cognitive deficits including impairment in at least two of the four core cognitive domains (impaired attention
which may fluctuate, impaired executive functions, impairment in visuo-spatial functions, and impaired free recall memory which
usually improves with cueing)
• The presence of at least one behavioral symptom (apathy, depressed or anxious mood, hallucinations, delusions, excessive daytime
sleepiness) supports the diagnosis of Probable PDD, lack of behavioral symptoms, however, does not exclude the diagnosis
3. None of the group III features present
4. None of the group IV features present
Possible PDD
1. Core features: Both must be present
2. Associated clinical features:
• Atypical profile of cognitive impairment in one or more domains, such as prominent or receptive-type (fluent) aphasia, or pure
storage-failure type amnesia (memory does not improve with cueing or in recognition tasks) with preserved attention
• Behavioral symptoms may or may not be present
OR
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3. One or more of the group III features present
4. None of the group IV features present
Adapted with permission from Emre et al. [123]. © 2007 Movement Disorder Society.
Table 4. Criteria for the diagnosis of probable and possible PDD.
All epidemiological studies assessing the progression to dementia in PD have observed a high
frequency of cognitive defects in patients without dementia; neuropsychological defects
indicative of predominant posterior cortical dysfunction have been associated to dementia
[125]. Along these lines, some investigations have examined whether cognitive performance
in the first stages of the disease could predict the future development of dementia. The results
obtained by different authors show that memory domain performance was a significant
predictor to develop PDD [87, 90, 126, 127], although other cognitive domains such as
attention [87], executive [128], visuospatial [82], and language [126] have also been identi‐
fied as predictors of the development of dementia. Once again, these outcomes can be
considered as evidence of the neuropathological heterogeneity associated with the evolution
of PD. Over time, progression of cognitive impairment in PD is explained by the deteriora‐
tion of the previously affected cognitive domains, but new symptoms and new cognitive
defects seem to have a special impact on the conversion to PDD. In a longitudinal study,
patients who developed PDD were characterized by the presence of defects in language
functions; the comparison between patients with PDD, Alzheimer's disease, and dementia
with Lewy bodies showed that the three groups had the same degree of difficulty in confron‐
tation naming [129].
On the other hand, different clinical and demographic variables have been associated with the
development of PDD and the most consistently reported are older age, lower education,
greater severity of motor symptoms and REM sleep behavior disorder [126, 130–133]. Visual
hallucinations have also been considered as a risk factor to develop dementia. In an 8-year
prospective study, the presence of visual hallucinations at baseline proved a significant
predictor of PDD [134]. A recent investigation with a sample of PD-MCI patients showed
that 50% of patients with visual hallucinations developed PDD, in contrast to 25% of pa‐
tients without hallucinations [135].
Recent studies have demonstrated that PD-MCI diagnosis is also associated with the devel‐
opment of dementia. The results described by different authors showed that patients who were
diagnosed with PD-MCI have an increased risk of developing PDD in the years following
diagnosis. In a 3 year longitudinal study with early PD patients, significantly more patients
with PD-MCI than PD patients with normal cognition progressed to dementia; among patients
with PD-MCI 27% developed PDD (annual progression rate of 9%), whereas only 0.7% of
patients with normal cognition developed PDD [87]. Domellöf et al. [88] conducted a 5 year
longitudinal study which included 115 PD patients with neuropsychological testing. Of the
115 patients, 31 (27%) developed PDD, which corresponds to an incidence rate of 62.6 per 1000
person-years. Forty-nine (42.6%) patients were classified as having MCI according to MDS
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criteria, of which 25 (51%) developed PDD within 5 years, corresponding to an incidence rate
of 142 per 1000 person-years. Similarly, Galtier et al. [90] showed that 42.3% of PD-MCI patients
had dementia in a six to eight follow up study, whereas in the group of PD patients with normal
cognition only 23.5% developed dementia during the follow up study. In addition, a 16 year
longitudinal study showed that 91% of PD-MCI patients had progressed to PDD [93].
Santangelo et al. [136] examined 76 patients who underwent neuropsychological testing at
baseline (Hoehn and Yahr stage 1–2), and at 2 and 4 years; 32.9% of PD patients had devel‐
oped PD-MCI at baseline (level 2). No patient went from PD-MCI to dementia after 2 years,
while 5.5% developed dementia after 4 years. The percentage of conversion to PDD is lower
than that reported in previous studies. The authors considered that a possible explanation for
this discrepancy might be found in the characteristics of our patients, who were relatively
young and had mild disease severity compared to other studies stated above.
6. Conclusions
In summary, the study of cognitive functions in PD has awakened much scientific and research
interest during the last 60 years. PD patients may even show cognitive deficits in the early
stages of the pathology, as has been confirmed in studies with newly diagnosed patients.
Cognitive impairment in PD is associated with alterations in different cognitive domains
including deficits in attention, executive, memory, visuospatial and language functions.
However, the heterogeneity in the manifestations and progression of these deficits is a
characteristic of the pathology. In addition, different clinical and demographic variables have
been linked to the evolution of cognitive impairment, with some of the most relevant being
neurological impairment, disease duration, older age and educational level. Diagnostic criteria
for PD-MCI and PDD have recently been developed and provide a uniform method to
characterize the evolution of cognitive impairment in PD and advance the understanding of
this pathology. The results demonstrate that PD-MCI is common in PD patients affecting
around 25% in the first stages and increasing to over 50% according to the progression of the
disease. Moreover, PD-MCI is considered a risk factor in the development of PDD, with a high
conversion rate to dementia in the years following the PD-MCI diagnosis.
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